Modality
Multispecific
MOA
HER2
Target
DLL3
Pathway
mTOR
MCLMigraine
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
→ Apr 2026
Phase 1Current
NCT04593283
1,362 pts·MCL
2021-07→2026-04·Not yet recruiting
1,362 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-243w awayPh2 Data· MCL
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1/2
Not yet…
Catalysts
Ph2 Data
2026-04-24 · 3w away
MCL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04593283 | Phase 1/2 | MCL | Not yet recr... | 1362 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| ARG-1924 | Argenx | Preclinical | DLL3 |